Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Predicted to enable G protein-coupled receptor binding activity; G-protein beta/gamma-subunit complex binding activity; and GTPase activity. Predicted to be involved in G protein-coupled adenosine receptor signaling pathway; adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; and gamma-aminobutyric acid signaling pathway. Predicted to act upstream of or within adenylate cyclase-modulating G protein-coupled receptor signaling pathway. Predicted to be located in centrosome. Predicted to be part of heterotrimeric G-protein complex. Predicted to be active in cytoplasm. Is expressed in several structures, including head; nervous system; paraxial mesoderm; pronephric duct; and vein. Orthologous to human GNAI2 (G protein subunit alpha i2). [provided by Alliance of Genome Resources, Feb 2025]